There has been a trend towards the development of novel vaginal dosage forms both for local therapy and systemic absorption. The growing number of vaginal dosage forms, however, presents with an increasing demand for appropriate in vitro test methods for ensuring a safe and reliable in vivo performance of each of the formulations. Application of biorelevant in vitro parameters, i.e., addressing in vivo parameters that significantly affect drug release from a vaginal dosage form in an in vitro test setup, could ensure that the results of the dissolution/drug release test are clinically meaningful and also predictive for detection of changes in the post-approval drug product. Thus, the development of predictive in vitro test methods for vaginal dosage forms is of great interest. A number of simulated vaginal fluids have been introduced in the recent past. In addition, several other genital fluids that could affect the intravaginal fluid composition, such as simulated cervical fluid/mucus, simulated intrauterine fluid, and simulated semen have been described in the literature. More frequent use of these media can be assumed, and future experiments will show if the current media will require more fine-tuning to even better reflect all physiological parameters that can affect drug release/dissolution in the vagina or if there is also a chance to simplify these media without losing their biorelevance.
INTRODUCTION

F
or many years, dissolution testing is a routine methodology to provide critical in vitro drug release information for both quality control purposes of solid oral dosage forms and in predicting the in vivo performance of a drug product in formulation development. For the latter purpose, over the past decades, several biorelevant dissolution methodologies addressing physiological parameters relevant to in vivo drug release of orally administered formulation have successfully been developed (1) . For many years, the focus of developing biorelevant dissolution test methods was set on obtaining predictive methods for oral dosage forms. However, as a result of a significant technologic advancement in drug delivery that has led to a wider choice of sites for drug administration, the development of predictive in vitro test methods for non-oral drug delivery systems is of great interest. Because it allows for both local and systemic drug delivery, in the recent past, the vagina has witnessed a surge of interest as a site for drug delivery. Dosage forms that can be administered vaginally include classical liquid, semisolid, or solid dosage forms, with creams and gels, suppositories, and tablets being the most commonly used vaginal formulations to date, but also newer types of formulations including, for instance, foams and films and novel delivery systems such as intravaginal rings (IVRs), have been released to the market or can be found in current development pipelines in the pharmaceutical industry.
For many years, vaginal dosage forms (VDFs) were mainly applied for local action in contraception, labor induction, the treatment of vaginal infections, and local menopausal symptoms (2) , and the vagina was a rather uncommon route for systemic drug administration. However, it was as early as 1918 when Macht et al. demonstrated that the vaginal epithelium can absorb different substances like alkaloids and inorganic salts (3) . These findings were supported by results from other research groups, e.g., in 1947, when Rock et al. could demonstrate that penicillin is easily absorbed from cocoa butter suppositories in the vagina of non-pregnant and post-partum women (4) . Nevertheless, even though the large surface area and blood supply of the vaginal epithelium allows for systemic drug delivery, for many years there were no efforts in developing VDFs for the administration of systemically acting drug compounds.
In the 1960s several studies focusing on steroid diffusivity through polysiloxane tubes and cylindrical elastomers were performed with regard to obtaining reservoir formulations that could be used as subdermal or intravaginal devices for controlled and long-term drug delivery (e.g. (5, 6) . In the following years, diffusivity of a large number of steroids, including medroxyprogesterone acetate (MPA), chlormadinone acetate, estradiol, progesterone, levonorgestrel in different elastomers, e.g., polysiloxanes and ethylene vinyl acetate was screened (6) (7) (8) (9) . In 1968, cylindrical elastomers of polysiloxane impregnated with MPA were fabricated and molded into rings suitable for placement in the vagina (10) . It took about 30 years of further development, before in 2001, the first combined (etonogestrel/ethinyl estradiol) contraceptive IVR, the NuvaRing®, was approved by the FDA. Since that, the interest in vaginal drug delivery with IVRs has significantly increased. Current trends in IVR development focus on addressing two or more indications from a single product. The overall goal for many of the combined products is to prevent unintended pregnancy and transmission of one or more sexually transmitted infections (STIs) including HIV (11) . Because there is currently a common interest in preventing the transmission of STIs, several other platforms are applied for developing VDFs for topical "on demand" prophylaxis for STI transmission or to provide spermicidal action. These include for instance also vaginal films, gels, and foams (12) .
The growing number of VDFs presents with an increasing demand for appropriate in vitro test methods for ensuring a safe and reliable in vivo performance of each of the formulations. Application of biorelevant in vitro parameters, i.e., addressing in vivo parameters that significantly affect in vivo drug release from the VDF in an in vitro test setup (fluid volume, pH, buffer capacity, viscosity and surface tension of the physiological fluids and ingredients (such as enzymes) that might affect drug release and stability) could ensure that the results of the dissolution/drug release test are clinically meaningful and also predictive for detection of changes in the postapproval drug product (13) . Therefore, establishing biopredictive test methods for VDFs should be of utmost importance for the developer. This review article should give an overview of test media that could be useful for (to a certain extent) simulating the physiological environment in the vagina and that, besides an appropriate instrumental setup, could be applied in the design of biorelevant test methods for VDFs. Moreover, to provide a better understanding of why also other genital fluids might be relevant for designing a biorelevant environment in the dissolution experiment, the anatomy of the female reproductive tract will be briefly discussed.
THE FEMALE REPRODUCTIVE SYSTEM
The vagina is part of the female reproductive system, which is immature at birth and develops to maturity during puberty. It connects the inner sex organs, i.e., the uterus, the fallopian tubes and the ovaries, with the external sex organs of the vulva (Fig. 1) . The vagina itself is a distensible muscular tube which is about 10 cm long. It serves as entrance to the reproductive tract and as exit from the uterus during menses and childbirth. Because of this particular anatomy, volume and composition of the fluid found in the vaginal cavity do not necessarily reflect the properties and the amount of fluid secreted by the vaginal epithelium but can also contain a certain amount of uterine fluid, cervical mucus and fallopian fluid and, after sexual intercourse, also semen. Therefore, volume and composition of the fluids produced in the female reproductive system are, moreover, impacted by age and stage of the menstrual cycle or pregnancy. Besides that, pathological conditions such as bacterial vaginosis, urinary tract infections, and cancer can impact the vaginal environment. Consequently, when setting up an in vitro test method for a particular VDF, these might also be important aspects to consider.
MEDIA SIMULATING HUMAN VAGINAL FLUID
The vaginal epithelium does not contain any glands. The fluid entering the vaginal cavity via the vaginal epithelium, i.e., the "real" vaginal fluid, transudates through the 
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www.dissolutiontech.com vaginal epithelium and consists of 90-95% water. The fluid that can be found in the vagina or is discharged from the vagina, respectively, is a mixture of transudated vaginal fluid with other secretions, such as those of Bartholin's and Skene's glands, which are located close to the vaginal orifice, cervical mucus, endometrial and tubal fluids. In addition, the fluid may also contain some residual urine and exfoliated epithelium cells. As a consequence, organic and inorganic salts, urea, carbohydrates, mucins, fatty acids, albumin, immunoglobulins, and other macromolecules can be found in vaginal fluid. The main function of the vaginal fluid is to moisten the vaginal epithelium (14) . The quantity and composition of human vaginal fluid (HVF) have been studied by various researchers and for different reasons. When screening the literature, it becomes clear that the results obtained in different studies strongly relate to the method of assessing vaginal fluid volumes and properties. Consequently, there is a large variation in the reported fluid volumes that enter the vagina over the duration of 24 h. Owen and Katz reported HVF secretion as 6 g/day (15) , whereas the corresponding secretion rate reported by Paavonen is only 1-3 g/day (14) . Wagner and Levin reported a production rate of 0.33 ± 0.05 g/h, which would correspond to 7.92 ± 1.2 g/day (16) . Vaginal resting fluid volumes seem to be less variable and are reported to be in the range of 0.5-0.75 g (15) or 0.5 mL (17) . As stated before, it should be noted, that both the amount of fluid entering the vagina as well as the vaginal resting fluid volume are subject to inter-and intraindividual variability and are affected by a number of essential parameters like age, phase of the menstrual cycle, and sexual stimulation.
Vaginal fluid pH in healthy pre-menopausal women is slightly acidic, which is caused by Lactobacilli that represent the most common microorganisms of the healthy vaginal flora. These microbes metabolize glycogen originating from glycogen deposits in vaginal epithelial cells into lactic acid, creating an acidic environment (18) . To a lesser extent, lactic acid is, however, also a significant metabolic byproduct of obligate anaerobic glucose metabolism within the vaginal mucosa. Overall, the vaginal pH is thus determined by the interplay between vaginal physiological processes and microbiology. In reproductive-age women, the average vaginal fluid pH is 4.5 (19) .
With the purpose of closely simulating a typical intravaginal environment for observing the binding and release characteristics of solutions of all-trans-retinoic acid (t-RA), from a collagen sponge diaphragm insert, the first artificial vaginal fluid (AVF, table 1) was developed in 1982 by Dorr et al. (20) . The AVF designed for these studies was intended to mimic the electrolyte, nitrogenous, and pH conditions of a normal HVF in an unstimulated state. Consequently, the media pH was set to 4.1, which is in the pH range of a healthy vaginal environment.
A few years later Geshnizgani and Onderdonk developed a vaginal fluid model (chemically defined medium, CDM) for studying the growth of the vaginal microflora under in vitro test conditions comparable to those in the human vagina (21) . The focus of the study was to investigate specific mechanisms and factors that control microbial populations. A key requirement for the CDM was to support the growth of all the bacterial species that make up a healthy human vaginal flora. Consequently, the medium was designed on the basis of published analyses of vaginal secretions. Potassium hydrogen-phosphate and potassium dihydrogen-phosphate were chosen as main buffering agents, cysteine hydrochloride was added as a reducing agent, and Tween 20 was added as a source of long-chain fatty acids and as growth stimulant for Lactobacillus species. Although published reports do not indicate the presence of other growth factors in vaginal fluids, most microorganisms require some additional growth factors in an in vitro environment. Consequently, the CDM was supplemented with a variety of additional growth factors. The preparation of CDM was performed in three separate steps (CDM parts I-III), comprising the preparation and mixing of a variety of stock solutions, before uniting them to the final medium. CDM part I (Tables 1 and 2 ) was prepared by dissolving the different ingredients in deionized water and adjusting the pH value to 7.20 with sodium hydroxide. Subsequently, the resulting solution was sterilized in an autoclave (121 °C, 15 min). In parallel, the different stock solutions for CDM part II (Table 2) were prepared separately and autoclaved or sterilized by filtration (0.22 µm). CDM part III (Table  2 ) was a commercially available vitamin mixture stock solution. After sterilization and equilibration to room temperature, CDM part I was mixed with appropriate amounts of the stock solutions of CDM part II and the vitamin stock solution of CDM part III to obtain CDM.
In 1999, Owen and Katz developed a vaginal fluid simulant (VFS, Table 1 ) based on data obtained from an intensive literature review on the composition of HVF (22) . After studying of how the physicochemical properties of native vaginal fluid, particularly the pH and osmolarity, affect the deployment and delivery of contraceptive and prophylactic compounds, VFS was specifically developed for addressing such impacts on in vitro dissolution/drug release testing of VDFs. The medium is intended to model vaginal fluid properties of healthy, non-pregnant and
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www. final concentration immediately before use. Overall, the media are quite easy to prepare and were found to be stable at 4 °C for 1 month.
Another medium that is often used to simulate vaginal conditions is acetate buffer, but even though it contains one of the essential organic acids, it does not represent additional components that can be found in HVF. The pH of acetate buffer can be set in a range of 4.0-4.5. Consequently, the buffer can mimic physiological pH conditions in the vagina. Moreover, acetate buffer is one of the standard buffers in routine dissolution testing, is easy to prepare, and has quite good storage stability, and therefore, is often the medium of choice in early formulation screening and quality control (QC) of VDFs (24) (25) (26) (27) (28) (29) .
MEDIA SIMULATING HUMAN CERVICOVAGINAL FLUID/MUCUS
Human cervical mucus serves as a lubricant, is a natural protective barrier, and has a clearance function. Table 3 ) to determine the influence of different mucin concentrations on the viscosity of cervical mucus (32) . As expected, the viscosity of AVF increased with increasing mucin concentrations. This observation was also in agreement with the in vivo findings reported by Morales et al., who observed proportional changes of mucin and viscosity levels throughout the menstrual cycle (33).
Overall, there are not many data available on the use of human cervicovaginal fluid/mucus in in vitro dissolution/ drug release testing. Most of the studies reported to date focused on properly mimicking mucus viscosity and how this parameter is affected by the stage of the menstrual cycle and sexual intercourse. With the aim of designing ideal mucus substitutes that are cheap, can be easily prepared, stable, and possess the same sperm penetrability characteristics as human cervical mucus, other groups evaluated hyaluronate solutions, egg white, albumin-containing Tyrode solution, bovine cervical mucus, or other polymer-based systems like polyacrylamide gels as human mucus substitutes. However, as indicated before, even though some of these media can resemble the properties of cervical mucus at certain stages in the menstrual cycle or before and after sexual intercourse, they are unlikely to become frequently used in in vitro dissolution/drug release testing since there are no dosage forms available that are exclusively applied to the cervix or the cervicovaginal region.
MEDIA SIMULATING HUMAN UTERINE FLUID
Uterine fluid has a complex composition that contains inorganic compounds, carbohydrates, lipid factors, amino acids, peptides, and proteins (34) . A simulated uterine fluid (SUF) can be required for in vitro drug release experiments with medicated intrauterine devices (IUDs) or for the investigation of copper corrosion of copperbearing IUDs (Cu-IUDs). The compositions of SUFs described in literature are given in Table 4 . (38) . A number of additional authors reported the use of SUFs in studying copper, zinc, or indometacin release from IUDs (40) (41) (42) (43) (44) (45) (46) (47) . However, in all of these studies, the media designed by Zhang et al. (35) or the slightly modified version reported by Mora et al. (39) were applied. In vivo uterine fluid enters the vagina via the cervix and mixes with the fluid secreted from the vaginal epithelium; therefore, to date, SUF has never been applied for studying drug release of VDFs as a stand-alone medium. However, its composition might become important when the intention is to compose a vaginal medium that addresses the composition of a physiologically relevant mixture of all fluids that enter the vagina and consequently may affect drug release of VDFs.
MEDIA SIMULATING HUMAN SEMINAL FLUID
During sexual intercourse, HVF mixes with seminal fluid. Human semen is a mixture of components produced by several different glands. During ejaculation, the different components are incompletely mixed. Since the different portions of the ejaculate have different origins, and the secretions of the organs contributing to the ejaculate differ in composition, the ejaculate is not an entirely homogeneous mixture. Overall, the fluid contains acid phosphatase, citric acid, inositol, calcium, zinc, magnesium, fructose, ascorbic acid, prostaglandins, L-carnitine, and neutral alpha-glucosidase, and several additional components (48) . The average human ejaculate volume was reported as 3.4 mL (48). Human seminal fluid (HSF) is slightly alkaline (pH 7.7) (48) and has a very high buffering capacity (25 slyke) (48) . Its (average) osmolality was reported as 354 mOsmol/kg (48) or in the range of 360-380 mOsmol/kg, respectively (17) . It is obvious that these properties of seminal fluid have an impact on the vaginal environment. Consequently pH, but also additional physicochemical properties of the mixture of vaginal and seminal fluid, should be considered when the aim is to develop vaginally applied formulations with a drug release/dissolution mechanism that can be affected by pH and other properties of the vaginal environment and that will be present in the vagina during sexual intercourse (e.g. IVRs, gels containing microbicides, etc.). Table 5 gives an overview of simulating seminal fluids described in literature.
Based upon an extensive literature review on the constituents of human semen, in 2005 Owen and Katz proposed a semen fluid simulant (SFS, Table 5 ) intended to be used for in vitro drug release/dissolution testing of VDFs (48) . In choosing the ingredients for this medium, a particular focus was set on achieving physiological properties that might have an impact on drug release/ dissolution of VDFs. Among these properties, pH and buffering capacity, osmolarity, ionic strength, and rheological properties usually play dominant roles in the physicochemical processes that govern drug release kinetics and delivery vehicle distribution. Even though it was not possible to match the concentration of every component and every physical parameter to the literature values, Owen and Katz tried to mimic the physiological properties as closely as possible.
In 2016, Rastogi et al. redesigned the SFS developed by Owen and Katz (48) and introduced two simplified SFS media (sSFS, Table 5 ). Analogous to the procedure reported for the sVFS, the sSFS should mimic the salient physicochemical properties of native seminal fluid, particularly the buffer capacity and osmolality, and were designed to be applicable for a variety of in vitro experiments (17) . As a first step, Rastogi et al. collected HSF and determined the buffer capacity. Then, they identified the major buffering species from published compositions of reproductive tract fluids. In the next step, ionic strength, buffering capacity, pH, and osmolalities of HSF were calculated or experimentally determined. Based on the SFS composition presented by Owen and Katz, they then designed two different sSFS media with finetuned ionic strength, osmolality, and buffer capacity. One medium, i.e. SFS+F, contains fructose and proteins; the other, SFS-F, does not. The media were designed as SFS+F and SFS-F 10x stock solution, which, as described for sVFS, can be easily diluted to their original concentration before use. Similar to sVFS, the media are easy to prepare and stable at 4 °C for 1 month.
Finally, with the aim of evaluating an artificial culture medium similar to seminal plasma with regard to its effect on the fine structure of human spermatozoa post- the main buffering species, and adjusting the osmolality. Bicarbonate was chosen as the main buffering species and the osmolality was adjusted to 320 ± 10 Osmol/kg by adding an appropriate amount of sodium chloride. Further, ascorbic acid, urate, and albumin were added to ASF as antioxidants. Finally, amongst other compounds, the medium contains glucose, fructose, lactate, and pyruvate, which are also naturally present in HSF as sources of energy.
DISCUSSION
The fluid available for drug release/dissolution in the human vagina is a mixture of fluids from different sources, such as glands located close to the vaginal orifice, cervix, endometrium, and fallopian tubes. Consequently, it contains numerous ingredients, and the composition and volume of HVF available in the human vagina at a given time point are subject to a high intra-and interindividual variability. Thus, the development of predictive in vitro test methods for VDFs is a challenge.
As discussed, several simulated vaginal fluids, also known as vaginal fluid simulants, have been introduced in the recent past. In addition, several other genital fluids that could affect the intravaginal fluid composition, such as simulated cervical fluid/mucus, simulated intrauterine fluid, and simulated semen have been described in the literature. It should be noted that many of these media were not (exclusively) developed for drug release/ dissolution testing and thus may not address all attributes of HVF that are relevant for drug release from vaginal drug formulations. Thus, the selection of an appropriate test medium should be made on a case-by-case basis.
However, for such a decision, a detailed understanding of the physiological conditions in the target patient group and the purpose of the experiment are essential. Whereas for many dosage forms, a detailed simulation of various factors such as fluid volume, secretion rate, and discharge, composition, and physicochemical properties of HVF are important to consider when designing biopredictive test methods. The development of appropriate QC methods presents with different challenges such as for instance, how to maintain sink conditions.
Since the resting fluid volume in the human vagina is rather small, particularly for formulations containing poorly soluble compounds, the use of physiological fluid volumes and physiologically based media is usually not feasible in QC of VDFs. When screening drug release from IVRs, i.e. devices that release the active pharmaceutical ingredient (API) over a duration of several weeks or even months, microbial stability of the media is another important issue that is usually not considered when designing physiologically relevant test media. The composition and physicochemical properties of many of the simulated genital fluids discussed in the present manuscript provide excellent conditions for the growth of undesired bacteria and molds when the test duration markedly exceeds ~24 hrs. When screening drug release from IVRs, the test medium must be completely replaced in short intervals or a preservative must be added to the medium. In the latter case, the preservative needs to be compatible with all other media ingredients and the formulation to be screened, i.e., it must not affect media properties and drug release or dissolution.
Most simulated genital fluids have a complex composition. Several ingredients, for instance, albumin, a protein that can also be found in human plasma and is well known to bind to numerous drug molecules (plasma protein binding) including several steroid hormones that are also applied in VDFs for contraceptive use, can significantly affect the concentration of free (dissolved) API in the test medium that is accessible by standard analytical techniques, such as UV spectrophotometry. Another problem that presents with media containing albumin or other proteins is protein precipitation in a non-aqueous or less-hydrophilic environment. This can be an issue, when samples need to be filtered before analysis. This situation can occur when preparing samples for liquid chromatography (LC) analysis, which often includes a step where aqueous samples from the release experiment are diluted with an organic solvent before injection. Precipitation can be an issue when samples need to be filtered before analysis (filter clogging), but also during sample analysis when the media composition is altered during analysis, e.g., by applying a solvent gradient in an LC run (column clogging). For these reasons, analytical methods applied in in vitro experiments with complex simulated genital fluids need to be properly validated to also capture API that might be bound to proteins or other ingredients of the test media after release/dissolution and to prevent technical problems during analysis. Due to the complex composition of simulated genital fluids, the development of appropriate analytical methods can be challenging, but these media can allow for simulating a variety of vaginal conditions in healthy and diseased pre-to post-menopausal women including the simulation of the vaginal milieu after sexual intercourse. The latter aspect is important for the evaluation of VDFs that stay in the vagina for several weeks (e.g. IVRs) or are inserted into the vagina immediately before sexual intercourse (e.g. vaginal gels). For simulating such conditions, an www.dissolutiontech.com appropriate in vitro test setup will need to implement the mixture of VFS and SFS after simulated intercourse. Such procedure is of particular importance when designing in vitro test methods for VDFs with contraceptive, microbicide, or spermicide action, which should not only exhibit a robust drug release in VFS, but also when physiological volumes of (simulated) vaginal fluid and (simulated) semen are mixed in vivo, which is usually accompanied by a temporary pH shift and an increase in buffer capacity of the vaginal contents. This shift can for instance alter the dissolution of drugs with pH-dependent solubility and/or the texture of vaginal gel formulations with pH-dependent viscosity (e.g. polyacrylate gels).
The design of both biopredictive test methods and QC tests for VDFs is not an easy task. The set of simulated genital fluids available to date is a reasonable platform for developing test methods for different VDFs, but it is also clear that there are still significant knowledge gaps regarding which physiological factors determine systemic and local bioavailability of APIs after application of different types of VDFs. Thus, it is more than likely that the overall design of in vitro test methods for VDFs, and particularly the composition and properties of the simulated genital fluids, might undergo sensible finetuning in the design of both QC and biopredictive studies.
CONCLUSION
A variety of simulated genital fluids are available for a range of different in vitro experiments. Some of these media have already been applied in in vitro release/ dissolution experiments, and others have not because researchers may not be aware of their existence or the media composition did not fit with the design or clinical significance of the experiment. However, with the increasing number of VDFs in current development pipelines, the simulated genital fluids available represent a promising platform for designing biopredictive test methods for VDFs. A more frequent use of these media can be assumed, and future experiments will show if the current media will require more fine-tuning to even better reflect all physiological parameters that can affect drug release/dissolution in the vagina or if there is also a chance to simplify these media without losing their biorelevance.
